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Abstract
The hepatitis C virus genotype 2a isolate, JFH-1, exhibits much more efficient genome replication than other isolates. Although 
basic replication mechanisms must be conserved, this raises the question of whether the regulation of replication might exhibit 
isolate- and/or genotype- specific characteristics. Exemplifying this, the phenotype of NS5A hyperphosphorylation is genotype- 
dependent; in genotype 1b a loss of hyperphosphorylation correlates with an enhancement of replication. In contrast, the repli-
cation of JFH-1 is not regulated by hyperphosphorylation. We previously identified a novel phosphorylation site in JFH-1 NS5A: 
S146. A phosphomimetic substitution (S146D) had no effect on replication but correlated with a loss of hyperphosphorylation. 
In genotype 1b, residue 146 is alanine and we therefore investigated whether the substitution of A146 with a phosphorylatable 
(S), or phosphomimetic, residue would recapitulate the JFH-1 phenotype, decoupling hyperphosphorylation from replication. 
This was not the case, as A146D exhibited both a loss of hyperphosphorylation and a reduction in replication, accompanied by 
a perinuclear restriction of replication complexes, reductions in lipid droplet and PI4P lipid accumulation, and a disruption of 
NS5A dimerization. In contrast, the S232I culture- adaptive mutation in the low- complexity sequence I (LCSI) also exhibited a 
loss of hyperphosphorylation, but was associated with an increase in replication. Taken together, these data imply that hyper-
phosphorylation does not directly regulate replication. In contrast, the loss of hyperphosphorylation is a consequence of per-
turbing genome replication and NS5A function. Furthermore, we show that mutations in either domain I or LCSI of NS5A can 
disrupt hyperphosphorylation, demonstrating that multiple parameters influence the phosphorylation status of NS5A.
InTRoduCTIon
Hepatitis C virus (HCV) is a leading cause of liver disease 
worldwide, with an estimated 71 million chronic infections 
that can ultimately lead to liver fibrosis, cirrhosis or hepatocel-
lular carcinoma [1]. HCV belongs to the family Flaviviridae, 
enveloped viruses with a positive- sense RNA genome (9.6 kb) 
coding for a single polyprotein that is processed co- and post- 
translationally by viral and host proteases, yielding four struc-
tural proteins (core, E1, E2 and p7) and six non- structural 
proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) [2].
Recently, virus genome replication has become the target 
for a number of potent direct- acting antivirals (DAAs) that 
have revolutionized therapy for HCV infection. These small 
molecule inhibitors are targeted directly to the NS3 protease, 
NS5B polymerase and NS5A. Although the mode of action 
of NS3 and NS5B inhibitors is well defined, it is not clear how 
NS5A inhibitors such as daclatasvir (DCV) function. NS5A is 
a phosphoprotein that has multiple functions in virus genome 
replication, assembly and modulation of host cell biology [3]. 
NS5A comprises three distinct domains (I–III), separated by 
short low- complexity sequences (LCSI and II) [4] (Fig. 1a). 
Three structural analyses of the well- conserved domain I 
revealed similar monomer structures that adopt different 
dimer conformations [5–7]. NS5A is highly phosphorylated 
[8], and two species with differing migration on SDS- PAGE 
are designated p56 (basal) and p58 (hyper). Phosphoryla-
tion of NS5A appears to be a highly regulated process and 
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several cellular kinases such as Polo- like kinase 1 (Plk1) [9] 
and casein kinase Iα (CKIα) [10, 11] have been implicated 
in hyperphosphorylation within the serine- rich LCSI. Phos-
phatidylinositol 4- kinase III alpha (PI4K- IIIα) [12] and CKII 
[13] have been implicated in basal phosphorylation, mainly 
in domains II/III [14, 15]; however, as yet, neither the kinases 
that phosphorylate NS5A nor the amino acid residues that are 
phosphorylated, have been unambiguously defined.
The first stage in addressing these important questions was 
to define the phosphorylation sites within NS5A. To this end, 
we [8], and others [10, 11, 16–18], used mass spectrometric 
Fig. 1. Role of NS5A residue 146 in genotype 1b RNA replication. (a) Schematic of NS5A structure showing amino acid residue numbers 
for Con1 and the location of A146 and S232. AH, amphipathic helix, LCS, low- complexity sequence. (b, c) Huh7.5 cells (4.3×106) were 
electroporated with in vitro transcripts of either wild- type Con1 SGR (CpG/UpA- low luciferase), NS5A mutants (A146S, A146L, A146D) 
with or without S232I substitution, or the NS5B GND mutant, seeded into 96- well plates and incubated for 4, 24, 48 and 72 h post- 
electroporation (p.e.). Absolute values of firefly luciferase activity are shown (b), together with values normalized to the 4 h p.e. reading 
(c). Error bars: sem, data from three independent experiments are shown. Significant differences from the wild- type are denoted by *** 
(P<0.001).
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approaches. In our study we showed that in the context of a 
subgenomic replicon (SGR), JFH-1 NS5A was phosphoryl-
ated on multiple serine residues, predominantly within LCSI. 
Mutagenesis revealed a role for a subset of these phosphoryla-
tion events in controlling genome replication [8]. The cluster 
of phosphorylation sites in LCSI was expected, as this had 
previously been described indirectly by mutagenesis [15], as 
well as by mass spectrometry [16]. Indeed, subsequent studies 
confirmed that LCSI is a major site for phosphorylation 
[10, 11, 17]. However, intriguingly, our analysis also identified 
a previously uncharacterized phosphorylated serine within 
domain I: S146 (Fig. 1a), corresponding to residue S2122 in 
the JFH-1 polyprotein (accession number AB047639). This 
residue was also identified independently in cells transfected 
with a non- replicating NS3- 5B expressing plasmid [18]. In 
both cases, mutagenesis of S146 had no effect on genome 
replication, but a phosphomimetic aspartate substitution 
(S146D) inhibited hyperphosphorylation. As S146 is ∼75 
residues N- terminal to LCSI, this observation implied that 
there was some crosstalk between domain I and LCSI to 
allow the regulation of hyperphosphorylation, for example 
the addition of a negative charge at residue 146 might result in 
a conformational change preventing hyperphosphorylation.
Interestingly, S146 is only present in genotype 1a and 2a 
isolates, and in the majority of other HCV isolates, including 
the prototype genotype 1b Con1 isolate, residue 146 is an 
alanine. The impact of residue 146 on the phosphorylation 
status of NS5A might therefore be exclusive to genotype 2a, 
and not a feature conserved throughout all HCV genotypes. 
In this context, the fact that the S146D- mediated inhibi-
tion of hyperphosphorylation did not affect JFH-1 genome 
replication contrasts with the situation for genotype 1b, 
where inhibition of hyperphosphorylation, for example as 
associated with the highly culture- adaptive S232I mutation 
within LCSI (polyprotein numbering S2204I in the genotype 
1b Con1 isolate, accession number Q9WMX2), enhanced 
replication [19–21]. This points to the conclusion that the 
factors affecting the phosphorylation status of NS5A differ 
between HCV genotypes.
In this study we sought to address this question by investi-
gating the role of residue 146 in the context of a genotype 
1b isolate (the prototypic Con1 strain) [22]. To do this we 
mutated this residue in a Con1 SGR to generate a phospho-
rylatable residue (A146S), or phosphomimetic (A146D), and 
compared the phenotype with the previously characterized 
culture- adaptive mutant S232I. Both S232I and A146D 
reduced NS5A hyperphosphorylation. However, whereas 
S232I exhibited the expected enhancement of genome replica-
tion, A146D reduced replication and altered the distribution 
of NS5A and other replication complex markers, restricting 
them to a perinuclear region. These data are consistent 
with the hypothesis that hyperphosphorylation of NS5A 
is dependent on multiple factors and in genotype 1b is not 
directly correlated with genome replicative capacity. In addi-
tion, we propose that both the protein structure and regula-
tion of NS5A function differ between different genotypes of 
HCV and that caution must be exercised in extrapolating data 
obtained from one isolate of the virus. In particular, JFH-1 
may not be representative of other genotypes.
RESuLTS
Role of residue 146 in Con1 genome replication and 
nS5A hyperphosphorylation
We had previously shown that hyperphosphorylation of 
JFH-1 NS5A was inhibited by a phosphomimetic mutation 
at residue S146 in domain I, in the absence of any concomitant 
effect on genome replication [8]. This contrasted with the situ-
ation in genotype 1b, where it had been previously reported 
that a loss of hyperphosphorylation correlated with enhanced 
replication [19–21], leading to the hypothesis that hyper-
phosphorylation negatively regulated genome replication. 
However, this observation in genotype 1b was exemplified 
by a culture- adaptive mutation, S232I, within LCSI, which 
presumably acted by directly disrupting the proposed hierar-
chical phosphorylation within this serine- rich sequence that 
has been associated with the hyperphosphorylated species. 
We therefore set out to ask whether residue 146 could also 
contribute to the regulation of hyperphosphorylation and/
or replication in genotype 1b, with a view to shedding more 
light on both the mechanisms and consequences of hyper-
phosphorylation. We mutated A146 (A2119 in polyprotein 
numbering) in the genotype 1b consensus (Con1) SGR to 
either serine or aspartate (A146S and A146D, respectively), 
and to control for potential phosphorylation- independent 
effects of residue 146, it was also mutated to leucine (A146L). 
To facilitate a comparative analysis of the phenotype of these 
mutants, we also generated the previously characterized 
culture adaptive mutation S232I (S2204I in polyprotein 
numbering), previously shown to abrogate hyperphospho-
rylation and increase SGR replication <20 000 fold [19]. Lastly, 
to assess any potential synergistic or anergistic effects of these 
mutants, we combined each of the three A146 mutants with 
S232I. In order to avoid the potential confounding effects of 
selection (which might result in additional mutations) we set 
out to perform these studies in a transient replication system. 
For this reason, we mutated the NS5A sequence in a Con1 
SGR that contained a modified firefly luciferase gene in which 
all CpG dinucleotides, and as many UpA dinucleotides as 
possible, were eliminated whilst retaining identical coding 
(kindly provided by Peter Simmonds, University of Oxford). 
This had been shown to result in a 100- fold enhancement of 
the replicative capacity of the Con1 SGR [23], comparable to 
the replication enhancement achieved in a similarly modified 
replicon for echovirus 7 [24], although the mechanism of this 
enhancement remains to be determined.
In vitro transcripts of the various mutant SGRs were elec-
troporated into Huh7.5 cells and genome replication was 
followed over 72 h by assaying luciferase activity (Fig. 1b) 
and normalized to the 4 h post- electroporation (p.e.) value to 
assess transfection efficiency and the translation of input RNA 
(Fig. 1c). All mutants were able to replicate, but a variety of 
phenotypes were observed: whereas A146D resulted in about 
a 1- log reduction in genome replication efficiency, replication 
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of A146S was similar to that of the wild- type. This was in 
contrast to the results previously observed for JFH-1, where 
mutation of S146 to either A or D had no effect on SGR 
replication or production of infectious virus [8]. The A146L 
mutation also had no effect on the level of genome replication. 
The addition of the S232I mutation significantly enhanced 
replication of the wild- type, A146S and A146L mutants, but 
only by <10- fold. This is considerably less than the original 
observation [19], but perhaps reflects the fact that the low 
CpG/UpA luciferase had already enhanced replication by 
approximately 100- fold. Interestingly, S232I did not exhibit 
a similar enhancement of the replication of the phospho-
mimetic A146D mutant, suggesting that the phenotype of 
A146D was dominant.
In the context of the JFH-1 SGR, the phosphomimetic S146D 
mutation resulted in a reduction in hyperphosphorylation 
[8, 25]. Our data showed that in Con1 the A146D muta-
tion, which would impart a negative charge at this position, 
was deleterious to genome replication. We thus proceeded 
to investigate this phenotype in more detail to determine 
whether it was also associated with alterations to NS5A 
hyperphosphorylation. To assess this, Huh7.5 cells electropo-
rated with Con1 SGRs were lysed at 48 h p.e. and analysed 
by SDS- PAGE/Western blotting (Fig. 2a). Total expression 
levels of NS5A normalized to GADPH, together with the ratio 
of hyper : basal- phosphorylated species, were determined 
(Fig. 2b, c). As expected, the wild- type SGR exhibited the 
characteristic two species of NS5A: p58 (hyperphosphoryl-
ated) and p56 (basal- phosphorylated). Neither the A146S nor 
the A146L mutations had any effect on the levels of NS5A 
expression or the p58 : p56 ratio. As seen for JFH-1, the phos-
phomimetic mutant A146D resulted in a significant reduction 
in NS5A hyperphosphorylation (Fig. 2a), and a modest reduc-
tion in the overall levels of NS5A expression. Furthermore, as 
previously demonstrated [19], the S232I substitution resulted 
in a complete loss of p58 – this was seen for the wild- type 
and all three A146 substitutions. These data show that a loss 
of NS5A hyperphosphorylation can be mediated via distinct 
mechanisms, and can correlate with either an enhancement 
(S232I) or the inhibition (A146D) of genome replication.
The A146d mutation perturbs replication complex 
formation
To further analyse the consequences of a loss of NS5A hyper-
phosphorylation, we examined the sub- cellular distribution 
of components of the replication complex [NS3, NS5A and 
phosphatidylinositol-4- phosphate (PI4P) lipids] by confocal 
microscopy. We had previously demonstrated that in cells 
harbouring the wild- type JFH-1 SGR or infected with JFH-1, 
NS5A was observed throughout the cytoplasm in discrete 
punctae. Whereas some phosphorylation site mutants, exem-
plified by S225A, resulted in a restricted perinuclear distri-
bution of NS5A and other replication complex components 
which correlated with a reduction in replication efficiency, 
S146A or S146D retained a wild- type distribution [25]. We 
therefore wished to test whether the Con1 A146D mutation, 
which was associated with a reduction in replication, also 
exhibited a restricted distribution. Huh7.5 cells were elec-
troporated with the SGR panel, prior to fixation and detection 
of NS5A by immunofluorescence and BODIPY staining for 
lipid droplets (LDs) (Fig. 3), as we had previously noted a 
juxtaposition of NS5A and LDs. The wild- type and all mutants 
except A146D exhibited a broad cytoplasmic distribution of 
bright punctate NS5A staining, juxtapositioned with LDs. The 
distribution of both NS5A and LDs in the case of A146D 
was restricted to a perinuclear region, although this restricted 
distribution was not as pronounced as that observed previ-
ously for JFH-1 S225A [25]. This was quantified by deter-
mining LD spatial distribution data for 12 randomly selected 
cells, confirming that A146D exhibited a clustering of LDs 
close to the nucleus in comparison to the wild- type and the 
other mutants (Fig. 4a). The total number of LDs per cell 
was also determined. As expected, there was a significant 
increase in LDs for the wild- type SGR compared to GND, 
and a reduced abundance in the A146D mutant compared to 
the wild- type (Fig. 4b). In contrast, the number of LDs in the 
A146S and A146L mutants was broadly comparable to that in 
the wild- type. The S232I mutant exhibited a modest increase 
in LD numbers, but this did not reach statistical significance.
Consistent with the 1- log reduction in the replication of 
A146D, there was also a reduction in the number of NS5A 
foci (data not shown). This was also apparent when SGR 
electroporated cells were co- stained for both NS5A and other 
replication complex components: NS3 (Fig. 5) and PI4P lipids 
(Fig. 6). For all the mutants there was a strong colocalization 
with NS3; this was expected, as the two proteins participate 
directly in the process of genome replication. PI4P is the 
product of PI4K activity, and NS5A has previously been 
reported to interact with, and activate, this cellular lipid kinase 
[12, 26]. The colocalization of NS5A and PI4P was deter-
mined, although interestingly this was not as pronounced 
as that observed for JFH-1 NS5A [25]; correlation values 
of ~0.5 were observed for the wild- type and most mutants 
(compared with ∼0.8 for JFH-1). Interestingly, for A146D and 
A146D/S232I both the number of PI4P punctae (Fig. 7) and 
the correlation values reduced significantly, consistent with a 
loss of colocalization. These data suggest that although A146D 
and A146D/S232I were able to replicate, they were impaired 
in their ability to recruit and activate PI4K. Of note, although 
S232I increased replication, it did not result in a concomitant 
increase in PI4P abundance.
Residue 146 influences dimerization of Con1 nS5A 
domain I
We [27], and others [28], have previously demonstrated that 
domain I of NS5A is able to dimerize in vitro. We also identi-
fied that residue P145 in JFH-1 NS5A was critical for this 
interaction, as a P145A mutation disrupted dimerization. 
Visual analysis of the ‘closed’ dimer form of genotype 1b 
NS5A domain I [6] revealed that both P145 and A146 were 
located in the dimer interface and this led us to ask whether 
residue 146 might also be involved in dimerization. To test 
this we expressed both Con1 wild- type and A146D domain 
I in Escherichia coli, and used GST- tagged domain I as bait 
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to precipitate His- tagged domain I, as described previously 
[27]. Fig.  8 shows that the A146D mutation significantly 
reduced the ability of Con1 domain I to dimerize, although 
compared to the negative control (JFH-1 P145A), A146D still 
exhibited dimer formation. These data are consistent with the 
hypothesis that in the context of Con1 residue 146 could be 
involved in the formation of the closed dimer form of NS5A.
dISCuSSIon
The results of this study demonstrate that in the context of 
the genotype 1b Con1 isolate, residue 146 of NS5A plays a 
role in the regulation of the genome replication, sub- cellular 
localization and dimerization of NS5A, with corresponding 
effects on NS5A hyperphosphorylation. The key observa-
tion is that both A146D and the previously characterized 
Fig. 2. Effect of A146 mutation on NS5A expression and phosphorylation. Huh7.5 cells were electroporated with in vitro transcripts of 
the indicated SGR and incubated for 48 h p.e. (a) Cells were lysed and analysed by SDS- PAGE/Western blot with a sheep polyclonal 
antiserum to NS5A [34] or mouse monoclonal antiserum to NS3. (b, c) Total NS5A levels and the ratio of hyper- to basal- phosphorylation 
were quantified from fluorescent Western blots. Error bars show sem; data from three independent experiments are shown.
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Fig. 3. Sub- cellular distribution of NS5A and lipid droplets (LDs) in Con1 SGR electroporated cells. Huh7.5 cells were electroporated with 
in vitro transcripts of the indicated SGRs, and the cells were seeded onto coverslips and incubated for 48 h prior to fixation. Cells were 
subsequently permeabilized and immunostained for NS5A (sheep anti- NS5A), with LD detection using BODIPY(558/568)- C12 dye, prior 
to imaging by confocal microscopy. White boxes indicate the area expanded in the right- hand panels.
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culture- adaptive mutation S232I exhibited a loss of NS5A 
hyperphosphorylation, yet, whereas A146D reduced replica-
tion, S232I, as expected, increased replication. This contrasts 
with previous studies on genotype 1b SGRs, where loss of 
hyperphosphorylation was associated with enhanced replica-
tion [19–21]. An explanation for these conflicting data is that, 
at least in the context of the Con1 SGR, hyperphosphorylation 
of NS5A does not directly regulate genome replication. In 
contrast, we believe that these results indicate that a loss of 
hyperphosphorylation is in fact a consequence of the pertur-
bation of replication complex formation and localization.
Further evidence for this hypothesis comes from the observa-
tion that although the regulation of hyperphosphorylation 
by residue 146 appears to be conserved in Con1 and JFH-1, 
the loss of hyperphosphorylation did not have any func-
tional consequences for JFH-1. Mutation of residue 146 had 
no effect on genome replication in the context of either an 
SGR or infectious virus, or the sub- cellular distribution of 
NS5A and other markers of replication complexes [8, 25]. 
In contrast, A146D in Con1 resulted in both a significant 
perinuclear restriction (Figs 3 and 4) and a reduction in the 
number of PI4P foci per cell (Figs 6 and 7), but this appears 
not to be related to hyperphosphorylation, as S232I had no 
effect on either parameter, yet also resulted in a loss of hyper-
phosphorylation (Fig. 2). Again, this points to the conclusion 
that loss of hyperphosphorylation is a consequence, rather 
than a cause, of these phenotypes.
The hyperphosphorylated form of NS5A is now generally 
accepted to be the result of the phosphorylation of multiple 
serine residues within LCSI, in particular S235 [17, 29]. In this 
regard, hyperphosphorylation can be directly disrupted by 
mutation of phosphoacceptor sites, and this is the mechanism 
by which S232I disrupts hyperphosphorylation. Sequential 
(also termed hierarchical) phosphorylation proceeds from 
Fig. 4. Quantification of lipid droplet (LD) distribution and abundance. (a) Spatial data for LDs were determined from 12 cells for each 
SGR using the GDSC plugin for Fiji. Box- and- whisker plots show the 10–90 % distribution for distance from the nuclear membrane. (b) 
Quantification of the total number of LDs per cell (c). Significant differences from the wild- type are denoted by *** (P<0.001).
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S232 to S235 and S238 within LCSI, and S232I would thus 
be predicted to disrupt this process. Indeed, the use of 
phosphospecific antibodies has shown that S232A blocked 
phosphorylation of S235 and S238, whereas S232D rescued 
these phosphorylation events [30].
A key question is therefore how might residue 146 influence 
the phosphorylation status of NS5A? As discussed previously 
[8], in genotype 1b residue 146 lies at the interface of the 
closed dimer structure [6], and it is plausible that, if this dimer 
structure was also present in JFH-1, phosphorylation at this 
residue could disrupt the closed dimer and favour either a 
monomer or the ‘open’ dimer configuration [5]. Phosphoryla-
tion at residue 146 could therefore result in both dynamic and 
reversible effects on LCSI hyperphosphorylation by imparting 
a negative charge at that residue, however, clearly such an 
effect cannot occur in genotype 1b (or other genotypes 
lacking a phosphorylatable residue at 146). The observation 
that the A146D mutation was associated with a significant 
reduction in the dimerization of domain I is consistent 
with the hypothesis that residue 146 is present within the 
dimer interface and contributes to dimerization. A146D is 
a phosphomimetic mutation and thus introduces a negative 
charge at this residue, which is likely to lead to conformational 
rearrangements in the protein, influencing both dimerization 
and hyperphosphorylation, and the observation that neither 
A146S nor A146L disrupt hyperphosphorylation (Fig. 2b) is 
Fig. 5. Colocalization of NS5A and NS3. Huh7 cells were electroporated with in vitro transcripts of the indicated SGRs, and seeded 
onto coverslips. At 48 h p.e. cells were fixed and immunostained for NS5A and NS3 (mouse monoclonal anti- NS3), prior to imaging by 
confocal microscopy. White boxes indicate the area expanded in the right- hand panels.
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Fig. 6. Colocalization of NS5A and the lipid phosphatidylinositol-4 phosphate (PI4P). Huh7 cells were electroporated with in vitro 
transcripts of the indicated SGRs, and seeded onto coverslips. At 48 h p.e. cells were fixed and immunostained for NS5A and PI4P 
lipids (mouse monoclonal), prior to imaging by confocal microscopy. White boxes indicate the area expanded in the right- hand panels. 
Colocalization scatter plots are of a 200×200 µm area containing >10 cells, and show the correlation of absolute values. The correlation 
value, r, is shown for each image.
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consistent with this hypothesis. Intriguingly, A146D appeared 
to exert a dominant replication phenotype, as in the context 
of A146D, S232I did not enhance replication as it did in a 
wild- type (A146) background. This is also consistent with 
the hypothesis that NS5A dimerization contributes to the 
establishment of a conformation competent for the initiation 
of a hierarchical phosphorylation cascade within LCSI. As 
further support for this, recent evidence has linked defects in 
dimerization to a loss of hyperphosphorylation [31], although 
it should be noted that in this study dimerization was deter-
mined by two- hybrid analysis and to date there has been no 
report of NS5A dimerization in HCV- infected cells.
Interpretation of the role of residue 146 is confounded by the 
fact that it is an alanine in the majority of HCV isolates, but 
in genotypes 1a, 1 c and 2a this residue is serine. As discussed 
above, the absence of a phosphorylatable residue at 146 in 
the vast majority of HCV isolates implies that the function 
cannot be directly affected by phosphorylation. The lack of 
phenotype for the Con1 A146S mutation, in comparison to 
the phosphomimetic A146D, implies that even when a phos-
phorylatable residue is present at 146, it is not a substrate 
for phosphorylation. Given that S146 phosphorylation was 
observed in JFH-1, this alludes to differences in the conforma-
tion of NS5A domain I between the two genotypes, such that 
residue 146 is not accessible to cellular kinases. This hypoth-
esis is supported by the observation that the phosphomimetic 
mutation at residue 146 only decreased genome replication in 
the context of the Con1 isolate, and not in JFH-1. It is note-
worthy that S146 phosphorylation per se is not incompatible 
with hyperphosphorylation, as pS146 was identified in both 
p56 and p58 species by mass spectrometry [18], even though 
this study also confirmed that the phosphomimetic S146D 
mutation was associated with a loss of hyperphosphorylation.
Taken together, our study reveals fundamental differences 
between HCV isolates with regard to both the structure of 
domain I and the regulation of NS5A function, and suggests 
that caution should be taken when extrapolating data obtained 
with the JFH-1 system, as these may not be generally applicable 
to all HCV genotypes. The availability of SGRs and infectious 
viruses derived from six of the seven genotypes [32, 33] will 
enable future comparative studies to address these ques-
tions. Our future efforts are focused on investigating the link 
between residue 146 and hyperphosphorylation in LCSI – we 
hope that a proteomic analysis comparing the wild- type with 
phosphorylation site mutants will reveal essential protein–
protein interactions that can help to explain our observations.
METHodS
Plasmids and mutagenesis
The CpG/UpA low luciferase SGR (SGR- luc- Con1) and 
the corresponding GND (NS5B polymerase defective) 
derivative were used throughout this study (a kind gift from 
Peter Simmonds, University of Oxford) [23]. Site- directed 
mutagenesis of NS5A was performed by generating overlap-
ping PCR fragments between MluI and XhoI restriction sites 
(657- nt), carrying the desired nucleotide exchange, and then 
cloning into SGR- luc- Con1 via flanking MluI/XhoI sites and 
confirming by sequencing.
Cell culture
Huh7.5 cells were cultured in Dulbecco's Modified Eagles 
Medium (DMEM) (Sigma) supplemented with 10 % foetal 
bovine serum (FBS), 100 IU penicillin ml−1, 100 µg strepto-
mycin ml−1 and 1 % non- essential amino acids in a humidified 
incubator at 37 °C, 5 % CO2.
Fig. 7. Quantification of NS5A:PI4P colocalization. Spatial data for PI4P lipids were determined from 12 cells for each SGR using the 
GDSC plug- in for Fiji; these data were used to determine the number of PI4P lipid punctae per cell.
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Electroporation of SGR RnA constructs
The preparation of in vitro transcripts and their electropora-
tion into Huh7 cells was conducted as described previously 
[8]. In brief, 4.5×106 Huh7.5 cells in diethylpyrocarbonate 
(DEPC) treated PBS were electroporated with 3 µg of in vitro 
RNA transcripts using a square wave protocol, 260 V and 
25 ms pulse. Subsequently, cells were resuspended in complete 
DMEM media and seeded at 1×104 cells cm−2 culture area, into 
either 12- or 6- well dishes.
Transient replication luciferase assays
Wild- type and mutant SGR- luc- Con1 RNAs were electropo-
rated into Huh7.5 cells, seeded into 96- well format and cell 
extracts were prepared at 4, 24, 48, and 72 h p.e. Luciferase 
activity was determined using the luciferase assay system 
(Promega) and a Biotrace M3 luminometer (Biotrace Ltd). 
Data points were obtained in triplicate, and experiments were 
repeated at least three times; representative data are given for 
each experiment.
SdS-PAGE/Western blot
Cells were washed twice in PBS, lysed in 1× Glasgow lysis 
buffer [GLB; 1 % (v/v) Triton X-100, 120 mM KCl, 30 mM 
NaCl, 5 mM MgCl2, 10 % (v/v) glycerol, 10 mM PIPES- 
NaOH, pH 7.2, with protease and phosphatase inhibitors] 
and harvested by centrifugation (2800 g, 10 min, 4 °C) before 
determining and normalizing protein concentration by BCA 
assay (Pierce). Following separation by SDS- PAGE, proteins 
Fig. 8. Residue 146 in domain I is involved in NS5A dimerization. (a) Input of GST and GST–domain I (35–215) (left), and His–SUMO–
domain I (35–215) (right), analysed by Western blotting with anti- GST or anti- His antibodies. (b) His- tagged domain I proteins were used 
as prey in pulldown assays with GST or GST–domain I, with corresponding mutations as bait. Precipitated proteins were analysed by 
Western blotting using anti- His and anti- GST antibodies. The ratio of His : GST was calculated following quantification of Western blot 
signals using a Li- Cor Odyssey Sa infrared imaging system and represented graphically as a measure of the dimerization activity. These 
data were representative of three independent experiments using different batches of purified domain I proteins. Significant differences 
from the wild- type are denoted by * (P<0.01) or *** (P<0.001).
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were transferred to a polyvinylidene difluoride (PVDF) 
membrane and blocked in 50 % (v/v) Odyssey blocking (OB) 
buffer (LI- COR) in PBS. The membrane was incubated with 
primary antibodies overnight at 4 °C, followed by secondary 
antibodies for 2 h at room temperature, both prepared in 
50 % OB buffer. The primary antibodies used were: anti- 
NS5A (sheep), 1 : 5000 [34]; anti- NS3 (mouse), 1 : 2 000; and 
anti- glyceraldehyde-3- phosphate dehydrogenase (GAPDH, 
mouse), 1 : 20 000 (Sigma). The secondary antibodies were 
anti- goat (800 nm) or anti- mouse (700 nm), used at 1 : 10 000 
prior to imaging fluorescence using a LI- COR Odyssey Sa 
infrared imaging system. Quantification of fluorescently 
labelled Western blots were carried out using Image Studio 
v3.1 (LI- COR) using a background subtraction method.
Immunofluorescence and confocal microscopy
Cells were washed with PBS before fixation for 20 min in 
4 % (w/v) PFA, and they were subsequently permeabilized 
in 0.1 % (v/v) Triton X-100, PBS and blocked with PBS- T, 
5 % (w/v) BSA before immunostaining with the denoted 
antibody. The primary antibodies used were: anti- NS5A 
(sheep), 1 : 1,000; anti- NS3 (mouse), 1 : 350; and anti- PI4P 
(mouse), 1 : 100 (Echelon). Various fluorescently conjugated 
secondary antibodies were used at 1 : 1000 (Life Technology). 
LDs were stained using the BODIPY (558/568)- C12 dye at 
1 : 5000 (Life Technology), added at the same time as the fluo-
rescent secondary antibody. Nuclei were counterstained with 
4′,6′- diamidino-2- phenylindole (DAPI). Confocal micros-
copy images were acquired on a Carl Zeiss LSM 880 inverted 
microscope, and post- acquisition analysis was conducted 
using Zen software (Zen version 2012 black edition 8.0, Zeiss, 
Germany).
Quantification of Lds
For the quantification of LD spatial arrangement, images were 
acquired with the same acquisition parameters, but with vari-
able gain to ensure correct exposure. The spatial coordinates 
of LDs were determined using the FindFoci function of the 
GDSC plugin for Fiji, with the nuclear envelope being manu-
ally outlined (utilizing the DAPI staining as reference) and 
coordinates generated by Fiji. The distance from each LD 
to the nuclear envelope was then determined using trigo-
nometry. LD spatial distribution data were generated for 12 
randomly selected cells for each replicon variant and the data 
were combined into a box- and- whisker plot.
GST-pulldown assay
The construction and purification of GST–domain I (GST- DI) 
and His–SUMO–domain I (His- SUMO- DI) were described 
previously [27]. Briefly, the coding sequence for either WT or 
mutant (A146D) domain 1 (amino acids 35 to 215) of Con1 
(genotype 1b) NS5A was amplified by PCR (and cloned into 
either pGEX6P-2 or pET28a- SUMO vectors to allow the 
expression of domain I N- terminally fused to either GST or 
a His- SUMO affinity tag. After purification, GST- DI and His- 
SUMO- DI were dialyzed into buffer (50 mM Tris- HCl, pH 
7.5, 100 mM NaCl, 5 mM MgCl2, 10 % glycerol, 0.5 % NP-40). 
A GST pulldown assay was performed as described previ-
ously [28]. Briefly, 10 µg of GST or GST fusion proteins 
were mixed with 5 µg of His- SUMO- DI in binding buffer 
containing 20 mM Tris- HCl, pH 7.2, 0.5 M NaCl, 200 mM 
KCl and 1 % NP-40 for 3 h at 4 °C on a rotating platform. Then 
the mixture was added to glutathione beads and incubated 
overnight at 4 °C. After washes using binding buffer, bound 
material was eluted with 50 µL of SDS sample buffer, heated 
for 10 min at 95 °C and separated by SDS- PAGE for Western 
blot analysis using anti- GST and anti- His antibodies.
Statistics
Datasets were analysed using Student’s t- test assuming a two- 
tailed, unequal variance to determine statistical difference 
from the wild- type. n=3 or greater throughout and *P<0.05, 
**P<0.01, ***P<0.001.
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